Novavax Q1 2024 GAAP EPS $(1.05) Beats $(1.06) Estimate, Sales $93.855M Miss $101.160M Estimate
Portfolio Pulse from Benzinga Newsdesk
Novavax reported Q1 2024 GAAP EPS of $(1.05), surpassing the $(1.06) estimate, marking a 69.21% improvement from last year. However, its sales of $93.855M fell short of the $101.160M estimate, despite a 15.94% increase from the previous year.
May 10, 2024 | 7:12 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Novavax's Q1 2024 earnings report showed a significant reduction in losses and a year-over-year sales increase, despite missing sales estimates.
The mixed results with an EPS beat but a miss on sales forecasts could lead to neutral short-term market reaction. The significant improvement in losses and sales growth year-over-year may be viewed positively, but the miss on sales estimates could temper optimism.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100